HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unilever Recalls Benzene-Tainted Antiperspirants, Cites Propellant

Executive Summary

Samples of two Suave 24-Hour Protection Aerosol Antiperspirants tested positive for “slightly elevated levels of benzene,” leading Unilever to recall all lots of the products that remain in circulation after the line’s discontinuation “for business reasons” in October 2021.

You may also be interested in...

Right Guard Antiperspirant Owners To Compensate Purchasers Nationwide In $1.95m Benzene Settlement

Henkel and Thriving Brands admit no wrongdoing, but have agreed to settle allegations in Connecticut federal court that they knowingly or negligently sold US consumers adulterated and misbranded antiperspirant products containing hazardous levels of benzene.

PCPC Challenges 2ppm Benzene Limit Cited By Valisure, Class Action Plaintiffs

In comments to the US FDA, PCPC provides a “highly conservative” risk assessment of benzene impurity in a dry shampoo product, showing that “even a benzene concentration of 15 ppm in a hypothetical aerosol dry shampoo product would have an acceptable level of risk for a lifetime of daily use.” The exercise was undertaken in response to Valisure’s petition for FDA regulatory action on benzene-tainted dry shampoos.

Valisure Alerts US FDA To Benzene In Dry Shampoos, Says Any Detected Level Could Be ‘Unacceptable’

Valisure found 70% of 148 tested dry shampoo batches contained ‘quantifiable’ benzene. The US FDA advises a strict 2ppm limit when benzene’s use is unavoidable to produce a drug product with a “significant therapeutic advance.” In dry shampoos, “any significant detection of benzene could be deemed unacceptable,” Valisure suggests in its 31 October citizen petition to the agency.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts